<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081172</url>
  </required_header>
  <id_info>
    <org_study_id>MSKCC-03144</org_study_id>
    <secondary_id>CDR0000360629</secondary_id>
    <nct_id>NCT00081172</nct_id>
  </id_info>
  <brief_title>Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate</brief_title>
  <official_title>A Phase II Trial Of Lu Radiolabeled Monoclonal Antibody HuJ591-GS (Lu-J591) In Patients With Metastatic Androgen-Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or&#xD;
      deliver radioactive tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well radiolabeled monoclonal antibody works in&#xD;
      treating patients with progressive metastatic androgen-independent adenocarcinoma (cancer) of&#xD;
      the prostate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the prostate-specific antigen (PSA) response rate in patients with progressive&#xD;
           metastatic androgen-independent adenocarcinoma of the prostate treated with lutetium Lu&#xD;
           177 monoclonal antibody J591.&#xD;
&#xD;
        -  Determine the measurable disease response rate in patients treated with this drug.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the duration of biochemical PSA and/or measurable disease response in patients&#xD;
           treated with this drug.&#xD;
&#xD;
        -  Determine the incidence of human anti-J591 antibody (HAHA) response in patients treated&#xD;
           with this drug.&#xD;
&#xD;
        -  Correlate hematological toxicity of this drug with bone marrow involvement (bone scan&#xD;
           index) in these patients.&#xD;
&#xD;
        -  Determine the survival rate in patients treated with this drug.&#xD;
&#xD;
        -  Determine the targeting of this drug to known tumor sites in these patients.&#xD;
&#xD;
        -  Determine the tumor-absorbed radiation dose in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open-label study.&#xD;
&#xD;
      Patients receive a single dose of lutetium Lu 177 monoclonal antibody J591 IV on day 1.&#xD;
      Patients then undergo radionuclide scanning between days 6-8 to confirm tumor targeting by&#xD;
      the study drug.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 17-32 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical response as measured by prostate-specific antigen level at 8 weeks after treatment</measure>
  </primary_outcome>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>lutetium Lu 177 monoclonal antibody J591</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Progressive disease after prior antiandrogen therapy, as evidenced by at least 1 of&#xD;
             the following parameters:&#xD;
&#xD;
               -  New osseous lesions on bone scan&#xD;
&#xD;
               -  Greater than 25% increase in the sum of the products of the longest perpendicular&#xD;
                  diameters of the lesions OR the appearance of new lesions on MRI or CT scan&#xD;
&#xD;
               -  Rising prostate-specific antigen (PSA) despite adequate medical or surgical&#xD;
                  castration therapy&#xD;
&#xD;
                    -  Consecutive increase in PSA, determined by two separate measurements taken&#xD;
                       at least 1 week apart and confirmed by a third, and if necessary, a fourth&#xD;
                       measurement&#xD;
&#xD;
                    -  PSA must be ≥ 5 ng/mL and ≥ 25% above the previous nadir&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Serum testosterone ≤ 50 ng/dL&#xD;
&#xD;
          -  No confluent lesions involving axial and appendicular skeleton on bone scan&#xD;
             (&quot;superscan&quot;)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 2,000/mm^3&#xD;
&#xD;
          -  Hematocrit ≥ 30%&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 150,000/mm^3&#xD;
&#xD;
          -  No serious hematologic illness that would preclude study participation&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  PTT normal&#xD;
&#xD;
          -  PT normal OR&#xD;
&#xD;
          -  INR normal&#xD;
&#xD;
          -  No serious hepatic illness that would preclude study participation&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.5 mg/dL&#xD;
&#xD;
          -  Calcium ≤ 11 mg/dL&#xD;
&#xD;
          -  No serious renal illness that would preclude study participation&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No active angina pectoris&#xD;
&#xD;
          -  No prior deep vein thrombophlebitis within the past 3 months&#xD;
&#xD;
          -  No other serious cardiac illness that would preclude study participation&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary embolus within the past 3 months&#xD;
&#xD;
          -  No other serious respiratory illness that would preclude study participation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No serious CNS illness that would preclude study participation&#xD;
&#xD;
          -  No active serious infection not controlled by antibiotics&#xD;
&#xD;
          -  No other serious illness that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 2 weeks since prior red blood cell or platelet transfusions&#xD;
&#xD;
          -  More than 2 weeks since prior hematopoietic growth factors&#xD;
&#xD;
          -  No prior monoclonal antibody therapy except ProstaScint®&#xD;
&#xD;
          -  No other concurrent monoclonal antibody-based therapy&#xD;
&#xD;
          -  No concurrent medication to support platelet count (e.g., oprelvekin)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent luteinizing hormone-releasing hormone (LHRH) analog allowed provided 1 of&#xD;
             the following is true:&#xD;
&#xD;
               -  Treatment is maintained during study participation&#xD;
&#xD;
               -  Treatment is terminated at least 10 weeks (for 1-month depot preparations), 24&#xD;
                  weeks (for 3-month depot preparations), or 32 weeks (for 4-month depot&#xD;
                  preparations) prior to study entry&#xD;
&#xD;
          -  More than 4 weeks since prior corticosteroids&#xD;
&#xD;
          -  More than 4 weeks since prior adrenal hormone inhibitors&#xD;
&#xD;
          -  Concurrent low-dose prednisone (≤ 5mg/day) for adrenal insufficiency allowed&#xD;
&#xD;
          -  No concurrent finasteride&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25% of skeleton&#xD;
&#xD;
          -  No prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium-containing&#xD;
             compounds (e.g., Metastron® or Quadramet®)&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior PC-SPES&#xD;
&#xD;
          -  More than 4 weeks since prior investigational therapy (medications or devices)&#xD;
&#xD;
          -  At least 1 week since prior aspirin and/or nonsteroidal anti-inflammatory agents&#xD;
             possessing antiplatelet activity&#xD;
&#xD;
          -  At least 1 week since prior antiplatelet medication, including the following:&#xD;
&#xD;
               -  Abciximab&#xD;
&#xD;
               -  Cilostazol&#xD;
&#xD;
               -  Clopidogrel&#xD;
&#xD;
               -  Dipyridamole&#xD;
&#xD;
               -  Ticlopidine&#xD;
&#xD;
          -  No concurrent anticoagulant medications (for platelet count &lt; 50,000/mm^3), including&#xD;
             the following:&#xD;
&#xD;
               -  Dalteparin&#xD;
&#xD;
               -  Danaparoid&#xD;
&#xD;
               -  Enoxaparin&#xD;
&#xD;
               -  Heparin&#xD;
&#xD;
               -  Warfarin&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Morris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Weill Cornell Cancer Center at Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

